NCT01959334View on ClinicalTrials.gov

Evaluate the Immunogenicity of a Novel Glucagon Formulation

PHASE3CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Drug-specific AntibodiesDiabetes Mellitus

Interventions

DRUG

Nasal Glucagon (NG)

DRUG

Glucagon IM

Trial Locations (1)

H7V 4B3

Algorithme Pharma Inc., Laval

Sponsors

Collaborators (1)

Locemia Solutions ULC

All Listed Sponsors

collaborator

Locemia Solutions ULC

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT01959334 - Evaluate the Immunogenicity of a Novel Glucagon Formulation | Biotech Hunter | Biotech Hunter